12 Feb 2021 07:00
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Posting of Circular
and
Notice of General Meeting
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that further to its announcement of the proposed Fundraising on 2 February 2021 (the "Placing Announcement"), a Circular, including the notice of General Meeting, a Form of Proxy and (where applicable) an Open Offer Application Form are today being posted to shareholders. The General Meeting will be held at 10:00 a.m. on 3 March 2021.
In light of the current restrictions in place with respect to the COVID-19 pandemic and, in particular, the UK Government's response (including guidance on working from home in place at the date of this notice), the Company's Board of Directors have concluded that the General Meeting will be held as a closed meeting. The Company will make arrangements such that the legal requirements to hold the General Meeting can be satisfied through the electronic attendance of the minimum number of shareholders, drawn from members of the Board. No other shareholder will be able to attend the General Meeting and are, instead, requested to complete the Form of Proxy, appointing the chairman of the meeting, rather than a third party, as their proxy by the relevant time.
Copies of the Circular and Form of Proxy will be made available on the Company's website www.evgen.com.
Capitalised terms used in this announcement shall have the same meanings as the definitions in the Placing Announcement unless otherwise defined herein.
Enquiries:
Evgen Pharma plc Barry Clare, Chairman Dr Huw Jones, CEO Richard Moulson, CFO
| Via Walbrook |
finnCap Geoff Nash / Teddy Whiley (Corporate Finance) Alice Lane / Sunila de Silva (ECM) www.finncap.com
| +44 (0) 20 7220 0500 |
Walbrook PR Paul McManus/ Anna Dunphy
| +44 (0)20 7933 87870 or evgen@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7876 741 001
|
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com